# ARIZONA STATE SENATE

## RESEARCH STAFF



#### MICHAEL MADDEN

LEGISLATIVE RESEARCH ANALYST HEALTH AND HUMAN SERVICES COMMITTEE

Telephone: (602) 926-3171

TO: MEMBERS OF THE OPIOID USE

DISORDER REVIEW COUNCIL

DATE: December 22, 2022

SUBJECT: Opioid Use Disorder Review Council 2022 Annual Report

\_\_\_\_\_

Attached is the 2022 annual report of the Opioid Use Disorder Review Council. This report has been distributed to the following individuals:

### Governor of the State of Arizona The Honorable Douglas A. Ducey

<u>President of the Senate</u> <u>Speaker of the House of Representatives</u>

Senator Karen Fann Representative Russel Bowers

Members of the Council

Senator Nancy Barto, Co-Chair Representative Joanne Osborne, Co-Chair

Don Herrington Representative Regina E. Cobb

Doray Elkins Tad Gary
Kim Humphrey Chris Jacques
Dr. Annette Lusko Dr. Daniel Ranieri

Dennis Regnier Dr. Flora Sadri-Azarbayejani

Jami Snyder Dr. Nirali Soni

#### Arizona State Library, Archives and Public Records

Secretary of the Senate

Senate Resource Center

Senate Republican Staff

Senate Democratic Staff

Senate Research Staff

House Republican Staff

House Democratic Staff

House Research Staff

House Chief Clerk

#### OPIOID USE DISORDER REVIEW COUNCIL

# ANNUAL REPORT December 22, 2022

### **Background**

Laws 2019, Chapter 224, established the Arizona Opioid Use Disorder Review Council (Council) consisting of 14 members, including opioid treatment (OTP) program representatives and administrators, family members of individuals who receive medically-assisted treatment (MAT) for opioid use disorder, members of the Legislature, and the Directors of the Department of Health Services and the Arizona Health Care Cost Containment System (AHCCCS). The Council is required to review and make recommendations to AHCCCS regarding: a) standards for designating Centers of Excellence (COE) for MAT; b) reporting requirements for care delivery activities in designated COEs; c) the availability of and barriers to all U.S. Food and Drug Administration-approved medications for treating opioid use disorder and whether utilization controls are appropriate; d) other state licensure and OTP models; and e) patient outcomes that are reported to AHCCCS by providers who receive reimbursement for opioid use disorder MAT. The Council is additionally authorized to recommend legislative changes to MAT-related laws. The Council terminates on January 1, 2024.

The Council is required to produce and submit a report, before December 15th of each year that details the Council's activities and recommendations to the Governor, the President of the Senate and the Speaker of the House of Representatives.

# Council Activity & Recommendations

The Council did not meet or adopt recommendations in 2022.